Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Recruiting now · Phase 3

Conditions studied: Relapsing Multiple Sclerosis

In brief

The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).

Key facts

Study ID
NCT06846281
Run by
Novartis Pharmaceuticals
People needed
360
Starts
2025-06-23
Expected to finish
2031-06-24
Last updated by the study team
2026-06-26

Who can join

Age: 40 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.